High-Dose Colchicine: Key Factor in the Treatment of Morbidly Obese COVID-19 Patients
Tsanko Mondeshki, Vanyo Mitev
Cureus, doi:10.7759/cureus.58164
Colchicine has long been known to possess anti-inflammatory effects by inhibiting microtubules, activation and migration of neutrophils, and most importantly, the inflammasome complex found in neutrophils and monocytes. Due to these properties, a number of clinical trials have tested the therapeutic effect of colchicine in COVID-19 patients. One common feature of these studies, however, is the low therapeutic dose used, which may explain the conflicting and disappointing results. Colchicine has the unique property of accumulating in leukocytes, which are primarily responsible for the hyperactivation of the NLRP3 inflammasome and the cytokine storm. The low-dose colchicine used to treat COVID-19 is not sufficient to reach the necessary intracellular concentration for NLRP3 inflammasome inhibition. We have reported our experience with high-dose colchicine, within the approved therapeutic range, in both ambulatory and hospitalized patients, and have shown dramatic cure rates. Here, we present our observation of an excellent therapeutic effect of high-dose colchicine in morbidly obese COVID-19 patients who are at the highest morbidity and mortality risk.
Additional Information Author Contributions All authors have reviewed the final version to be published and agreed to be accountable for all aspects of the work.
Concept and design: Vanyo Mitev
References
Ahmed-Khan, Matar, Coombes, Moin, Joseph et al., Remdesivir-associated acute liver failure in a COVID-19 patient: a case report and literature review, Cureus,
doi:10.7759/cureus.34221Deng, Li, Zhang, Zhao, Wang, Targeting inflammasome activation in viral infection: a therapeutic solution?, Viruses,
doi:10.3390/v15071451Ellulu, Patimah, Khaza'ai, Rahmat, Abed, Obesity and inflammation: the linking mechanism and the complications, Arch Med Sci,
doi:10.5114/aoms.2016.58928Hendren, De Lemos, Ayers, Association of body mass index and age with morbidity and mortality in patients hospitalized with COVID-19: results from the American Heart Association COVID-19 Cardiovascular Disease Registry, Circulation,
doi:10.1161/CIRCULATIONAHA.120.051936Jin, Yang, Chen, Zhang, Duan, Endothelial activation and dysfunction in COVID-19: from basic mechanisms to potential therapeutic approaches, Signal Transduct Target Ther,
doi:10.1038/s41392-020-00454-7Kadiyska, Tourtourikov, Dabchev, Role of endothelial dysfunction in the severity of COVID-19 infection (review), Mol Med Rep,
doi:10.3892/mmr.2022.12867Kalligeros, Shehadeh, Mylona, Benitez, Beckwith et al., Association of obesity with disease severity among patients with coronavirus disease 2019, Obesity,
doi:10.1002/oby.22859Lilov, Palaveev, Mitev, High doses of colchicine act as "silver bullets" against severe COVID-19, Cureus,
doi:10.7759/cureus.54441Mitev, Comparison of treatment of COVID-19 with inhaled bromhexine, higher doses of colchicine and hymecromone with WHO-recommended Paxlovid, molnupiravir, remdesivir, anti-IL-6 receptor antibodies and baricitinib, Pharmacia,
doi:10.3897/pharmacia.70.e112550Mondeshki, Bilyukov, Mitev, Effect of an accidental colchicine overdose in a COVID-19 inpatient with bilateral pneumonia and pericardial effusion, Cureus,
doi:10.7759/cureus.35909Mondeshki, Bilyukov, Tomov, Mihaylov, Mitev, Complete, rapid resolution of severe bilateral pneumonia and acute respiratory distress syndrome in a COVID-19 patient: role for a unique therapeutic combination of inhalations with bromhexine, higher doses of colchicine, and hymecromone, Cureus,
doi:10.7759/cureus.30269Petrakis, Margină, Tsarouhas, Obesity -a risk factor for increased COVID-19 prevalence, severity and lethality (review), Mol Med Rep,
doi:10.3892/mmr.2020.11127Singh, Rathore, Khan, Association of obesity with COVID-19 severity and mortality: an updated systemic review, meta-analysis, and meta-regression, Front Endocrinol,
doi:10.3389/fendo.2022.780872Tiholov, Lilov, Georgieva, Palaveev, Tashkov et al., Effect of increasing doses of colchicine on the treatment of 333 COVID-19 inpatients, PREPRINT,
doi:10.22541/au.171008530.09561084/v1Who, Obesity, Overweight, None
Zhou, Hill, Sarkar, β-d-N4-hydroxycytidine inhibits SARS-CoV-2 through lethal mutagenesis but is also mutagenic to mammalian cells, J Infect Dis,
doi:10.1093/infdis/jiab247{ 'indexed': {'date-parts': [[2024, 4, 14]], 'date-time': '2024-04-14T00:24:35Z', 'timestamp': 1713054275112},
'reference-count': 20,
'publisher': 'Springer Science and Business Media LLC',
'content-domain': {'domain': [], 'crossmark-restriction': False},
'published-print': {'date-parts': [[2024, 4, 13]]},
'DOI': '10.7759/cureus.58164',
'type': 'journal-article',
'created': {'date-parts': [[2024, 4, 13]], 'date-time': '2024-04-13T07:51:35Z', 'timestamp': 1712994695000},
'source': 'Crossref',
'is-referenced-by-count': 0,
'title': 'High-Dose Colchicine: Key Factor in the Treatment of Morbidly Obese COVID-19 Patients',
'prefix': '10.7759',
'author': [ {'given': 'Tsanko', 'family': 'Mondeshki', 'sequence': 'first', 'affiliation': []},
{'given': 'Vanyo', 'family': 'Mitev', 'sequence': 'additional', 'affiliation': []}],
'member': '297',
'reference': [ { 'key': 'ref1',
'doi-asserted-by': 'publisher',
'DOI': '10.3892/mmr.2020.11127',
'article-title': 'Obesity\xa0‑\xa0a risk factor for increased COVID‑19 prevalence, '
'severity and lethality (review)',
'volume': '22',
'author': 'Petrakis D',
'year': '2020',
'unstructured': 'Petrakis D, Margină D, Tsarouhas K, et al.. Obesity\xa0‑\xa0a risk '
'factor for increased COVID‑19 prevalence, severity and lethality '
'(review). Mol Med Rep. 2020, 22:9-19. 10.3892/mmr.2020.11127',
'journal-title': 'Mol Med Rep'},
{ 'key': 'ref2',
'doi-asserted-by': 'publisher',
'DOI': '10.3389/fendo.2022.780872',
'article-title': 'Association of obesity with COVID-19 severity and mortality: an updated '
'systemic review, meta-analysis, and meta-regression',
'volume': '13',
'author': 'Singh R',
'year': '2022',
'unstructured': 'Singh R, Rathore SS, Khan H, et al.. Association of obesity with '
'COVID-19 severity and mortality: an updated systemic review, '
'meta-analysis, and meta-regression. Front Endocrinol (Lausanne). 2022, '
'13:780872. 10.3389/fendo.2022.780872',
'journal-title': 'Front Endocrinol (Lausanne)'},
{ 'key': 'ref3',
'doi-asserted-by': 'publisher',
'DOI': '10.1002/oby.22859',
'article-title': 'Association of obesity with disease severity among patients with '
'coronavirus disease 2019',
'volume': '28',
'author': 'Kalligeros M',
'year': '2020',
'unstructured': 'Kalligeros M, Shehadeh F, Mylona EK, Benitez G, Beckwith CG, Chan PA, '
'Mylonakis E. Association of obesity with disease severity among patients '
'with coronavirus disease 2019. Obesity (Silver Spring). 2020, 28:1200-4. '
'10.1002/oby.22859',
'journal-title': 'Obesity (Silver Spring)'},
{ 'key': 'ref4',
'doi-asserted-by': 'publisher',
'DOI': '10.1161/CIRCULATIONAHA.120.051936',
'article-title': 'Association of body mass index and age with morbidity and mortality in '
'patients hospitalized with COVID-19: results from the American Heart '
'Association COVID-19 Cardiovascular Disease Registry',
'volume': '143',
'author': 'Hendren NS',
'year': '2021',
'unstructured': 'Hendren NS, de Lemos JA, Ayers C, et al.. Association of body mass index '
'and age with morbidity and mortality in patients hospitalized with '
'COVID-19: results from the American Heart Association COVID-19 '
'Cardiovascular Disease Registry. Circulation. 2021, 143:135-44. '
'10.1161/CIRCULATIONAHA.120.051936',
'journal-title': 'Circulation'},
{ 'key': 'ref5',
'doi-asserted-by': 'publisher',
'DOI': '10.1038/s41392-020-00454-7',
'article-title': 'Endothelial activation and dysfunction in COVID-19: from basic '
'mechanisms to potential therapeutic approaches',
'volume': '5',
'author': 'Jin Y',
'year': '2020',
'unstructured': 'Jin Y, Ji W, Yang H, Chen S, Zhang W, Duan G. Endothelial activation and '
'dysfunction in COVID-19: from basic mechanisms to potential therapeutic '
'approaches. Signal Transduct Target Ther. 2020, 5:293. '
'10.1038/s41392-020-00454-7',
'journal-title': 'Signal Transduct Target Ther'},
{ 'key': 'ref6',
'doi-asserted-by': 'publisher',
'DOI': '10.3892/mmr.2022.12867',
'article-title': 'Role of endothelial dysfunction in the severity of COVID‑19 infection '
'(review)',
'volume': '26',
'author': 'Kadiyska T',
'year': '2022',
'unstructured': 'Kadiyska T, Tourtourikov I, Dabchev K, et al.. Role of endothelial '
'dysfunction in the severity of COVID‑19 infection (review). Mol Med Rep. '
'2022, 26:351. 10.3892/mmr.2022.12867',
'journal-title': 'Mol Med Rep'},
{ 'key': 'ref7',
'unstructured': 'WHO. Obesity and overweight. (2024). '
'https.//www.who.int/news-room/fact-sheets/detail/obesity-and-overweight.'},
{ 'key': 'ref8',
'doi-asserted-by': 'publisher',
'DOI': '10.5114/aoms.2016.58928',
'article-title': 'Obesity and inflammation: the linking mechanism and the complications',
'volume': '13',
'author': 'Ellulu MS',
'year': '2017',
'unstructured': "Ellulu MS, Patimah I, Khaza'ai H, Rahmat A, Abed Y. Obesity and "
'inflammation: the linking mechanism and the complications. Arch Med Sci. '
'2017, 13:851-63. 10.5114/aoms.2016.58928',
'journal-title': 'Arch Med Sci'},
{ 'key': 'ref9',
'doi-asserted-by': 'publisher',
'DOI': '10.7759/cureus.30269',
'article-title': 'Complete, rapid resolution of severe bilateral pneumonia and acute '
'respiratory distress syndrome in a COVID-19 patient: role for a unique '
'therapeutic combination of inhalations with bromhexine, higher doses of '
'colchicine, and hymecromone',
'volume': '14',
'author': 'Mondeshki T',
'year': '2022',
'unstructured': 'Mondeshki T, Bilyukov R, Tomov T, Mihaylov M, Mitev V. Complete, rapid '
'resolution of severe bilateral pneumonia and acute respiratory distress '
'syndrome in a COVID-19 patient: role for a unique therapeutic '
'combination of inhalations with bromhexine, higher doses of colchicine, '
'and hymecromone. Cureus. 2022, 14:e30269. 10.7759/cureus.30269',
'journal-title': 'Cureus'},
{ 'key': 'ref10',
'doi-asserted-by': 'publisher',
'DOI': '10.22541/au.171008530.09561084/v1',
'article-title': 'Effect of increasing doses of colchicine on the treatment of 333 '
'COVID-19 inpatients. [PREPRINT]',
'author': 'Tiholov R',
'year': '2024',
'unstructured': 'Tiholov R, Lilov A, Georgieva G, Palaveev K, Tashkov K, Mitev V. Effect '
'of increasing doses of colchicine on the treatment of 333 COVID-19 '
'inpatients. [PREPRINT]. Authorea. 2024, '
'10.22541/au.171008530.09561084/v1',
'journal-title': 'Authorea'},
{ 'key': 'ref11',
'doi-asserted-by': 'publisher',
'DOI': '10.7759/cureus.35909',
'article-title': 'Effect of an accidental colchicine overdose in a COVID-19 inpatient '
'with bilateral pneumonia and pericardial effusion',
'volume': '15',
'author': 'Mondeshki T',
'year': '2023',
'unstructured': 'Mondeshki T, Bilyukov R, Mitev V. Effect of an accidental colchicine '
'overdose in a COVID-19 inpatient with bilateral pneumonia and '
'pericardial effusion. Cureus. 2023, 15:e35909. 10.7759/cureus.35909',
'journal-title': 'Cureus'},
{ 'key': 'ref12',
'doi-asserted-by': 'publisher',
'DOI': '10.3897/pharmacia.70.e112550',
'article-title': 'Comparison of treatment of COVID-19 with inhaled bromhexine, higher '
'doses of colchicine and hymecromone with WHO-recommended Paxlovid, '
'molnupiravir, remdesivir, anti-IL-6 receptor antibodies and baricitinib',
'volume': '70',
'author': 'Mitev V',
'year': '2023',
'unstructured': 'Mitev V. Comparison of treatment of COVID-19 with inhaled bromhexine, '
'higher doses of colchicine and hymecromone with WHO-recommended '
'Paxlovid, molnupiravir, remdesivir, anti-IL-6 receptor antibodies and '
'baricitinib. Pharmacia. 2023, 70:1177-93. 10.3897/pharmacia.70.e112550',
'journal-title': 'Pharmacia'},
{ 'key': 'ref13',
'doi-asserted-by': 'publisher',
'DOI': '10.7759/cureus.54441',
'article-title': 'High doses of colchicine act as “silver bullets” against severe '
'COVID-19',
'volume': '16',
'author': 'Lilov A',
'year': '2024',
'unstructured': 'Lilov A, Palaveev K, Mitev V. High doses of colchicine act as “silver '
'bullets” against severe COVID-19. Cureus. 2024, 16:e54441. '
'10.7759/cureus.54441',
'journal-title': 'Cureus'},
{ 'key': 'ref14',
'doi-asserted-by': 'publisher',
'DOI': '10.3389/fimmu.2020.01518',
'article-title': 'Targeting the NLRP3 inflammasome in severe COVID-19',
'volume': '11',
'author': 'Freeman TL',
'year': '2020',
'unstructured': 'Freeman TL, Swartz TH. Targeting the NLRP3 inflammasome in severe '
'COVID-19. Front Immunol. 2020, 11:1518. 10.3389/fimmu.2020.01518',
'journal-title': 'Front Immunol'},
{ 'key': 'ref15',
'doi-asserted-by': 'publisher',
'DOI': '10.7759/cureus.34221',
'article-title': 'Remdesivir-associated acute liver failure in a COVID-19 patient: a case '
'report and literature review',
'volume': '15',
'author': 'Ahmed-Khan MA',
'year': '2023',
'unstructured': 'Ahmed-Khan MA, Matar G, Coombes K, Moin K, Joseph BM, Funk CM. '
'Remdesivir-associated acute liver failure in a COVID-19 patient: a case '
'report and literature review. Cureus. 2023, 15:e34221. '
'10.7759/cureus.34221',
'journal-title': 'Cureus'},
{ 'key': 'ref16',
'doi-asserted-by': 'publisher',
'DOI': '10.1093/infdis/jiab247',
'article-title': 'β-d-N4-hydroxycytidine inhibits SARS-CoV-2 through lethal mutagenesis '
'but is also mutagenic to mammalian cells',
'volume': '224',
'author': 'Zhou S',
'year': '2021',
'unstructured': 'Zhou S, Hill CS, Sarkar S, et al.. β-d-N4-hydroxycytidine inhibits '
'SARS-CoV-2 through lethal mutagenesis but is also mutagenic to mammalian '
'cells. J Infect Dis. 2021, 224:415-9. 10.1093/infdis/jiab247',
'journal-title': 'J Infect Dis'},
{ 'key': 'ref17',
'doi-asserted-by': 'publisher',
'DOI': '10.1136/bmj.n2663',
'article-title': 'Buyer beware: molnupiravir may damage DNA',
'volume': '375',
'author': 'van Schalkwyk JM',
'year': '2021',
'unstructured': 'van Schalkwyk JM. Buyer beware: molnupiravir may damage DNA. BMJ. 2021, '
'375:n2663. 10.1136/bmj.n2663',
'journal-title': 'BMJ'},
{ 'key': 'ref18',
'doi-asserted-by': 'publisher',
'DOI': '10.3390/v15071451',
'article-title': 'Targeting inflammasome activation in viral infection: a therapeutic '
'solution?',
'volume': '15',
'author': 'Deng CH',
'year': '2023',
'unstructured': 'Deng CH, Li TQ, Zhang W, Zhao Q, Wang Y. Targeting inflammasome '
'activation in viral infection: a therapeutic solution?. Viruses. 2023, '
'15:1451. 10.3390/v15071451',
'journal-title': 'Viruses'},
{ 'key': 'ref19',
'unstructured': 'How many people die from the flu?. (2022). '
'https.//ourworldindata.org/influenza-deaths.'},
{ 'key': 'ref20',
'doi-asserted-by': 'publisher',
'DOI': '10.1080/13102818.2023.2288240',
'article-title': 'What is the lowest lethal dose of colchicine?',
'volume': '37',
'author': 'Mitev V',
'year': '2023',
'unstructured': 'Mitev V. What is the lowest lethal dose of colchicine?. Biotechnol '
'Biotechnol Equip. 2023, 37:2288240. 10.1080/13102818.2023.2288240',
'journal-title': 'Biotechnol Biotechnol Equip'}],
'container-title': 'Cureus',
'original-title': [],
'language': 'en',
'link': [ { 'URL': 'https://www.cureus.com/articles/239046-high-dose-colchicine-key-factor-in-the-treatment-of-morbidly-obese-covid-19-patients',
'content-type': 'unspecified',
'content-version': 'vor',
'intended-application': 'similarity-checking'}],
'deposited': { 'date-parts': [[2024, 4, 13]],
'date-time': '2024-04-13T07:51:40Z',
'timestamp': 1712994700000},
'score': 1,
'resource': { 'primary': { 'URL': 'https://www.cureus.com/articles/239046-high-dose-colchicine-key-factor-in-the-treatment-of-morbidly-obese-covid-19-patients'}},
'subtitle': [],
'short-title': [],
'issued': {'date-parts': [[2024, 4, 13]]},
'references-count': 20,
'URL': 'http://dx.doi.org/10.7759/cureus.58164',
'relation': {},
'ISSN': ['2168-8184'],
'subject': [],
'published': {'date-parts': [[2024, 4, 13]]}}
